Tag Archives: UK

The United Kingdom: Rx for America's Pharma Tax Blues?

by Tom Norton The dizzying flurry of press releases from both Pfizer Inc. and AstraZeneca over a possible PFE acquisition of AZN have Rx experts on both sides of the Atlantic buzzing… From the US side, the most frequent thing that I have heard over the last 48 hours is, “You have got to be […]
Posted in Corporate Responsibility, Deals, Europe, FDA, Global, Guest Blog, leadership, Legal, People, Strategy | Also tagged , , , , , , , | 1 Comment

Pfizer’s AZ Bid Draws Mixed UK Reaction

The confirmation of Pfizer’s bid for an outright acquisition of AstraZeneca has drawn mixed reactions from the UK. Linda McCulloch of Britain’s biggest union, Unite, said the bid is “very worrying for the UK workforce”, adding that it is “absolutely crucial” that there should be “guarantees of no jobs losses and for the protection on the UK’s […]
Posted in Deals, Europe, Global, Supply Chain | Also tagged , , | Leave a comment

Pursuing the 'Real' Cost Effectiveness Threshold in England

By Leela Barham. The Incremental Cost Effectiveness Ratio (ICER) thresholds used by agencies such as the UK’s National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and as far afield as Australia by the Pharmaceutical Benefits Advisory Committee (PBAC) are often controversial. This is mostly because it means analysts saying that a […]
Posted in Europe, Guest Blog, Op-Ed, pricing | Also tagged , , , , , , , , , | Leave a comment

Pricing and Reimbursement in Europe: Where Does Innovation Fit?

By Leela Barham. It was recently said, in reference to the UK’s Value-Based Assessment(VBA) program, that innovation had not been “tried and tested in the pricing context”, which explains the loss of the “innovation” criteria from the proposals formerly known as Value-Based Pricing (VBP). This prompted me to think about just how has innovation been […]
Posted in Europe, Global, Guest Blog, pricing, R&D | Also tagged , , , , | Leave a comment

UK: Lord Saatchi's Innovation Bill Divides Healthcare Community

By Leela Barham. Few would argue with the desirability of innovation — something new, something that delivers value. And innovation in pharmaceuticals is a range from a more convenient way for patients to take a medicine, to treating a disease that couldn’t be treated before. Pretty much everyone will agree that not only do they […]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , | Leave a comment
  • Categories

  • Meta